Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
Learn More2021
Company EstablishedOver US $100 M
Closed Financing70 +
Company Members29
PCT Patent Submitted30 +
Pipelines5
5 clinical stageArgo Biopharma specializes in siRNA drug discovery and development. Our industry-leading siRNA platform technology, RADS (RNA molecules with superior Activity, Durability, and Safety), is the cornerstone of our innovative approach. Based on this platform, drugs can achieve the expected one injection per year in clinical practice in some indications.
Learn MoreAs a platform company, Argo Biopharma has a rich product pipelines covering a wide range of indications: cardiovascular diseases, rare diseases, CNS diseases, viral hepatitis, metabolic diseases, etc.
Learn MoreWith its cutting-edge siRNA platform technology, RADS, Argo Biopharma is able to provide Best-In-Class candidates for a range of indications.
Argo's extensive pipeline encompasses a wide range of therapeutic areas, including cardiovascular, metabolic disorders, hematological, CNS, hepatitis, and complement mediated diseases. We recognize that collaborating with other organizations can expedite the advancement of our novel medications towards clinical trials and eventual commercialization. To expand our wide pipelines, we are open to out-licensing, asset acquisitions, and strategic partnerships.
Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.
Learn MoreShanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.
Argo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.
Argo Biopharma’s first siRNA drug approved for clinical study in China, the United States, and Australia.
为了更好的呈现效果，移动端请竖屏浏览
